Sasini Polwatta Lekamlage, Alexandra N Boix De Jesus, Adriana Machado Saraiva, Catherine Drummond, Harrison Dolan, Francesc March de Ribot, Janice A Royds, Sunali Mehta, Antony W Braithwaite, Noelyn A Hung, Tania L Slatter
{"title":"Δ133p53 isoform enhances TLR4 function to promote tumour growth.","authors":"Sasini Polwatta Lekamlage, Alexandra N Boix De Jesus, Adriana Machado Saraiva, Catherine Drummond, Harrison Dolan, Francesc March de Ribot, Janice A Royds, Sunali Mehta, Antony W Braithwaite, Noelyn A Hung, Tania L Slatter","doi":"10.1093/carcin/bgaf051","DOIUrl":null,"url":null,"abstract":"<p><p>Tumour protein 53 (TP53) acts as a tumour suppressor and is often mutated in cancer. Isoforms of TP53, such as the Δ133p53 family, can promote tumour growth and metastasis. Therefore, targeting Δ133p53 function may represent a new strategy for preventing tumour metastasis. To inform the identification of proteins to target in Δ133p53-expressing tumours, changes at the cell surface were characterised. Inhibition of cell surface trafficking in a mouse model syngrafted with tumours expressing proteins similar to Δ133p53 (Δ122p53) was associated with reduced tumour growth and metastasis. After confirming that changes at the cell surface were important for Δ133p53 tumour promotion, characterisation of protein changes at the Δ133p53/Δ122p53 cell surface revealed increased expression of the toll-like receptor 4 (TLR4) and the TLR4 agonist, apoptosis inhibitor 5. Furthermore, inhibition of TLR4 was sufficient to reduce Δ122p53 tumour growth. Altogether, these results suggest a role for Δ133p53 in contributing to tumour progression by stimulating TLR4 function. Furthermore, targeting changes at the cell surface can reduce Δ133p53 tumour promotion.</p>","PeriodicalId":9446,"journal":{"name":"Carcinogenesis","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Carcinogenesis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/carcin/bgaf051","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Tumour protein 53 (TP53) acts as a tumour suppressor and is often mutated in cancer. Isoforms of TP53, such as the Δ133p53 family, can promote tumour growth and metastasis. Therefore, targeting Δ133p53 function may represent a new strategy for preventing tumour metastasis. To inform the identification of proteins to target in Δ133p53-expressing tumours, changes at the cell surface were characterised. Inhibition of cell surface trafficking in a mouse model syngrafted with tumours expressing proteins similar to Δ133p53 (Δ122p53) was associated with reduced tumour growth and metastasis. After confirming that changes at the cell surface were important for Δ133p53 tumour promotion, characterisation of protein changes at the Δ133p53/Δ122p53 cell surface revealed increased expression of the toll-like receptor 4 (TLR4) and the TLR4 agonist, apoptosis inhibitor 5. Furthermore, inhibition of TLR4 was sufficient to reduce Δ122p53 tumour growth. Altogether, these results suggest a role for Δ133p53 in contributing to tumour progression by stimulating TLR4 function. Furthermore, targeting changes at the cell surface can reduce Δ133p53 tumour promotion.
期刊介绍:
Carcinogenesis: Integrative Cancer Research is a multi-disciplinary journal that brings together all the varied aspects of research that will ultimately lead to the prevention of cancer in man. The journal publishes papers that warrant prompt publication in the areas of Biology, Genetics and Epigenetics (including the processes of promotion, progression, signal transduction, apoptosis, genomic instability, growth factors, cell and molecular biology, mutation, DNA repair, genetics, etc.), Cancer Biomarkers and Molecular Epidemiology (including genetic predisposition to cancer, and epidemiology), Inflammation, Microenvironment and Prevention (including molecular dosimetry, chemoprevention, nutrition and cancer, etc.), and Carcinogenesis (including oncogenes and tumor suppressor genes in carcinogenesis, therapy resistance of solid tumors, cancer mouse models, apoptosis and senescence, novel therapeutic targets and cancer drugs).